Seinda Pharmaceutical Guangzhou

Guangzhou Seinda Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's primary focus is on oncology, with a pipeline centered on high-selectivity kinase inhibitors for the treatment of solid tumors and hematological malignancies. Its lead candidate, SD-91, is a potent CDK4/6 inhibitor currently in Phase 1 clinical trials for advanced breast cancer. Seinda leverages its internal medicinal chemistry and pharmacology platforms to advance candidates from early discovery through clinical proof-of-concept. The firm is situated within the Guangzhou Science City biotech cluster and maintains a strong focus on addressing unmet medical needs in the Chinese market.